StreetInsider.com News Articles

New Analysis of Over 50 Studies Showed that All the Non-Prescription CBD Products Researched Fell Short of Therapeutic Efficacy — Reinforcing the Case for Artelo's Optimized ART12.11 CBD Compos

Wed, 22 Jul 2026 08:39:00 -0400

Review Article Now Published in the British Journal of Clinical Pharmacology Finds Widely Sold Non-Prescription CBD Products at Doses Administered Failed to Provide Adequate Exposure for Positive Biological Effect

Underscores the Need for Optimized CBD Formulations and Rigorous, Evidence-Based Drug Development

SOLANA BEACH, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Artelo” or the “Company”), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological, and neurological conditions, today announced the publication of an article titled, "Evaluating

New Analysis of Over 50 Studies Showed that All the Non-Prescription CBD Products Researched Fell Short of Therapeutic Efficacy — Reinforcing the Case for Artelo's Optimized ART12.11 CBD Compos

Wed, 22 Jul 2026 08:39:00 -0400

Review Article Now Published in the British Journal of Clinical Pharmacology Finds Widely Sold Non-Prescription CBD Products at Doses Administered Failed to Provide Adequate Exposure for Positive Biological Effect

Underscores the Need for Optimized CBD Formulations and Rigorous, Evidence-Based Drug Development

SOLANA BEACH, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL)  (“Artelo” or the “Company”), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological, and neurological conditions, today announced the publication of an article titled, "Evaluating

New Analysis of Over 50 Studies Showed that All the Non-Prescription CBD Products Researched Fell Short of Therapeutic Efficacy — Reinforcing the Case for Artelo's Optimized ART12.11 CBD Compos

Wed, 22 Jul 2026 08:39:00 -0400

Review Article Now Published in the British Journal of Clinical Pharmacology Finds Widely Sold Non-Prescription CBD Products at Doses Administered Failed to Provide Adequate Exposure for Positive Biological Effect

Underscores the Need for Optimized CBD Formulations and Rigorous, Evidence-Based Drug Development

SOLANA BEACH, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL)  (“Artelo” or the “Company”), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological, and neurological conditions, today announced the publication of an article titled, "Evaluating

New Analysis of Over 50 Studies Showed that All the Non-Prescription CBD Products Researched Fell Short of Therapeutic Efficacy — Reinforcing the Case for Artelo's Optimized ART12.11 CBD Compos

Wed, 22 Jul 2026 08:39:00 -0400

Review Article Now Published in the British Journal of Clinical Pharmacology Finds Widely Sold Non-Prescription CBD Products at Doses Administered Failed to Provide Adequate Exposure for Positive Biological Effect

Underscores the Need for Optimized CBD Formulations and Rigorous, Evidence-Based Drug Development

SOLANA BEACH, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL)  (“Artelo” or the “Company”), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological, and neurological conditions, today announced the publication of an article titled, "Evaluating

Form 4 ARTELO BIOSCIENCES, INC. For: Jul 17 Filed by: MATSUI CONNIE

Tue, 21 Jul 2026 18:32:00 -0400
si-local-file:///var/storage/secattach/20260721/26796755.html

Form 4 ARTELO BIOSCIENCES, INC. For: Jul 17 Filed by: MATSUI CONNIE

Tue, 21 Jul 2026 18:32:00 -0400
si-local-file:///var/storage/secattach/20260721/26796755.html

Form 4 ARTELO BIOSCIENCES, INC. For: Jul 17 Filed by: Blayney Douglas

Tue, 21 Jul 2026 18:30:00 -0400
si-local-file:///var/storage/secattach/20260721/26796753.html

Form 4 ARTELO BIOSCIENCES, INC. For: Jul 17 Filed by: Blayney Douglas

Tue, 21 Jul 2026 18:30:00 -0400
si-local-file:///var/storage/secattach/20260721/26796753.html

Form 4 ARTELO BIOSCIENCES, INC. For: Jul 17 Filed by: Reyes Gregory

Tue, 21 Jul 2026 18:29:00 -0400
si-local-file:///var/storage/secattach/20260721/26796748.html

Form 4 ARTELO BIOSCIENCES, INC. For: Jul 17 Filed by: Reyes Gregory

Tue, 21 Jul 2026 18:29:00 -0400
si-local-file:///var/storage/secattach/20260721/26796748.html

Form 4 ARTELO BIOSCIENCES, INC. For: Jul 17 Filed by: EMANUELE ROBERT MARTIN

Tue, 21 Jul 2026 18:27:00 -0400
si-local-file:///var/storage/secattach/20260721/26796747.html

Form 4 ARTELO BIOSCIENCES, INC. For: Jul 17 Filed by: EMANUELE ROBERT MARTIN

Tue, 21 Jul 2026 18:27:00 -0400
si-local-file:///var/storage/secattach/20260721/26796747.html

Form 4 ARTELO BIOSCIENCES, INC. For: Jul 17 Filed by: Kelly Steven

Tue, 21 Jul 2026 18:26:00 -0400
si-local-file:///var/storage/secattach/20260721/26796746.html

Form 4 ARTELO BIOSCIENCES, INC. For: Jul 17 Filed by: Kelly Steven

Tue, 21 Jul 2026 18:26:00 -0400
si-local-file:///var/storage/secattach/20260721/26796746.html

Form 4 ARTELO BIOSCIENCES, INC. For: Jul 17 Filed by: FAVORITO TAMARA A

Tue, 21 Jul 2026 18:25:00 -0400
si-local-file:///var/storage/secattach/20260721/26796741.html

Form 4 ARTELO BIOSCIENCES, INC. For: Jul 17 Filed by: FAVORITO TAMARA A

Tue, 21 Jul 2026 18:25:00 -0400
si-local-file:///var/storage/secattach/20260721/26796741.html

Form 8-K ARTELO BIOSCIENCES, INC. For: Jul 17

Fri, 17 Jul 2026 16:35:00 -0400
si-local-file:///var/storage/secattach/20260717/26784765.html

Form 8-K ARTELO BIOSCIENCES, INC. For: Jul 17

Fri, 17 Jul 2026 16:35:00 -0400
si-local-file:///var/storage/secattach/20260717/26784765.html

Form DEFA14A ARTELO BIOSCIENCES, INC.

Thu, 16 Jul 2026 13:19:00 -0400
si-local-file:///var/storage/secattach/20260716/26778848.html

Form DEFA14A ARTELO BIOSCIENCES, INC.

Thu, 16 Jul 2026 13:19:00 -0400
si-local-file:///var/storage/secattach/20260716/26778848.html

Artelo Biosciences reports nonclinical OA pain data for ART26.12

Thu, 16 Jul 2026 08:48:30 -0400

Artelo Biosciences, Inc. (Nasdaq: ARTL) announced nonclinical study results showing its FABP5 inhibitor ART26.12 reduced osteoarthritis-associated pain behaviors in animals, according to a company press release.
The data were presented by Martin Kaczocha, Ph.D., Professor of Anesthesiology at Stony Brook University, at the International Cannabinoid Research Society 2026 Annual Symposium held in Dijon, France.
In the study, oral administration of ART26.12 reduced pain behaviors following both acute and chronic dosing over a four-week period. The compound showed efficacy comparable to naproxen, a commonly used nonsteroidal anti-inflammatory drug (NSAID). Animals treated with ART26.12 showed significantly less stomach tissue damage, including non-glandular hyperkeratosis, compared

Artelo Biosciences reports nonclinical OA pain data for ART26.12

Thu, 16 Jul 2026 08:48:30 -0400

Artelo Biosciences, Inc. (Nasdaq: ARTL) announced nonclinical study results showing its FABP5 inhibitor ART26.12 reduced osteoarthritis-associated pain behaviors in animals, according to a company press release.
The data were presented by Martin Kaczocha, Ph.D., Professor of Anesthesiology at Stony Brook University, at the International Cannabinoid Research Society 2026 Annual Symposium held in Dijon, France.
In the study, oral administration of ART26.12 reduced pain behaviors following both acute and chronic dosing over a four-week period. The compound showed efficacy comparable to naproxen, a commonly used nonsteroidal anti-inflammatory drug (NSAID). Animals treated with ART26.12 showed significantly less stomach tissue damage, including non-glandular hyperkeratosis, compared

Artelo Biosciences Announces Results from a Nonclinical Osteoarthritis Study Supporting ART26.12 as a Potential First-in-Class New Therapy for Chronic Pain Conditions

Thu, 16 Jul 2026 08:48:00 -0400

SOLANA BEACH, Calif., July 16, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Artelo” or the “Company”), a clinical-stage pharmaceutical company focused on modulating lipid-signalling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced new data supporting the therapeutic potential of ART26.12, its proprietary and selective fatty acid binding protein 5 (FABP5) inhibitor, as a novel product candidate for the treatment of osteoarthritis (OA) pain. Martin Kaczocha, Ph.D., Professor of Anesthesiology at Stony Brook University, New York, presented the research results at the International Cannabinoid Research Society 2026

Artelo Biosciences Announces Results from a Nonclinical Osteoarthritis Study Supporting ART26.12 as a Potential First-in-Class New Therapy for Chronic Pain Conditions

Thu, 16 Jul 2026 08:48:00 -0400

SOLANA BEACH, Calif., July 16, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Artelo” or the “Company”), a clinical-stage pharmaceutical company focused on modulating lipid-signalling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced new data supporting the therapeutic potential of ART26.12, its proprietary and selective fatty acid binding protein 5 (FABP5) inhibitor, as a novel product candidate for the treatment of osteoarthritis (OA) pain. Martin Kaczocha, Ph.D., Professor of Anesthesiology at Stony Brook University, New York, presented the research results at the International Cannabinoid Research Society 2026

Artelo Biosciences Announces Results from a Nonclinical Osteoarthritis Study Supporting ART26.12 as a Potential First-in-Class New Therapy for Chronic Pain Conditions

Thu, 16 Jul 2026 08:48:00 -0400

SOLANA BEACH, Calif., July 16, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Artelo” or the “Company”), a clinical-stage pharmaceutical company focused on modulating lipid-signalling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced new data supporting the therapeutic potential of ART26.12, its proprietary and selective fatty acid binding protein 5 (FABP5) inhibitor, as a novel product candidate for the treatment of osteoarthritis (OA) pain. Martin Kaczocha, Ph.D., Professor of Anesthesiology at Stony Brook University, New York, presented the research results at the International Cannabinoid Research Society 2026